Clinical Trial for Ripretinib
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
Clinical trials are an essential part of medical research, aimed at introducing new procedures and treatments to the public.
Clinical trials are scientific research studies done in humans that help us to understand whether a new treatment is safe and effective in treating an illness, such as cancer.
Starting in January, every Wednesday will be dedicated learning about clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST).
This summary article helps explain the results of Deciphera's Phase 3 INTRIGUE trial as published in Future Medicine, authored by Marina Symcox & Robin L Jones.
Theseus Pharmaceuticals announced yesterday the discontinuation of enrollment in the Phase 1/2 study and terminating the development of THE-630 for GIST patients with advanced or metastatic GIST. The company reported dose-limiting toxicities relating to [...]
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
In this summary, we continue highlighting recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
December 2021 - In this summary, we have highlighted recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
Dr. David Josephy and Jim Hughes discuss clinical trials for GISTers and what you need to know.